Onconova sinks on 2nd Phase III rigosertib bust
This article was originally published in Scrip
Executive Summary
Onconova Therapeutics plunged 37.4% in after-hours trading to $8.68 per share on 19 February after the company said its PI3K and PLK inhibitor rigosertib failed in the Phase III ONTIME clinical trial in high-risk myelodysplastic syndromes (MDS).
You may also be interested in...
Asia Deal Watch: China’s BravoVax, US-based GeoVax Team Up On Coronavirus Vaccine
Deal news from GeoVax/BravoVax, Onconova/HanX, Zydus Cadila/China Medical System Holdings, EyePoint/Ocumension, Ningbo NewBay Medical/Genentech, Otsuka/PhoreMost, Almirall/WuXi Biologics
Sage’s Dalzanemdor Prospects In Doubt After First Mid-Stage Readout
Dalzanemdor (SAGE-718) showed no difference from placebo in a Phase II Parkinson’s disease study, raising concerns about readouts later this year in Huntington’s and Alzheimer’s diseases.
First Phase III Depression Data For Intra-Cellular’s Caplyta Exceed Expectations
With positive results from the first Phase III trial of lumateperone in major depressive disorder and a second readout expected later this quarter, the company plans a supplemental filing in late 2024.